Novo Nordisk A/S NVO shares are trading higher Monday after the company announced European Union approval for oral semaglutide to reduce cardiovascular death, heart attack and stroke.
What To Know: : The European Medicines Agency’s Committee for Medicinal Products for Human Use approved an update to the Rybelsus (oral semaglutide) label to reflect cardiovascular benefits demonstrated in the SOUL trial. The phase 3b study displayed Rybelsus reduced the risk of major adverse cardiovascular events — a composite of cardiovascular death, heart attack and stroke — by 14% versus placebo in adults with type 2 diabetes at high cardiovascular risk.
The company stated new SOUL results will also be presented this week at the European Association for the Study of Diabetes annual meeting, highlighting reduced hospitalizations and consistent cardiovascular benefits across body weight categories.
How To Buy Novo Nordisk Shares
By now you’re likely curious about how to participate in the market for Novo Nordisk NVO – be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to purchase “fractional shares,” which allows you to own portions of stock without purchaseing an entire share.
If you’re viewing to bet against a company, the process is more complex. You’ll required access to an options trading platform, or a broker who will allow you to “go short” a share of stock by lfinishing you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either purchase a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.
See Also: Inside Helius Medical’s $500 Million Raise — And Its Solana Treasury Plans
NVO Price Action: At the time of writing, Novo Nordisk shares are trading 1.90% higher at $55.91, according to data from Benzinga Pro.
Image via Shutterstock
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.












Leave a Reply